Sham Mailankody

Sep 18, 2024 | nature.com | Malin Hultcrantz |Hani Hassoun |Neha Korde |Kylee H. Maclachlan |Sham Mailankody |Urvi A. Shah | +9 more

Letter to the EditorLenalidomide is an immunomodulatory drug that is recommended and widely used as part of induction therapy and maintenance for multiple myeloma (MM) [1]. Lenalidomide maintenance is associated with significantly improved progression-free and overall survival, as shown in several clinical trials and meta-analyses [2,3,4,5,6,7]. Most patients tolerate lenalidomide well; however, fatigue and diarrhea are common side effects in the maintenance phase [3, 7, 8].

Jun 24, 2024 | targetedonc.com | Sham Mailankody

Case: A 70-Year-Old Man with Early Relapse Multiple MyelomaClinical Presentation:A 70-year-old man who was diagnosed 5 years ago with R-ISS stage 2/R2-ISS stage III lenalidomide refractory IgG-kappa multiple myeloma presents to his oncologist after two prior treatment regimens. Lives in a rural communityPMH: hypertension controlled with lisinopril. Prior Treatments:Patient received previous treatments with:D-VRd followed by ASCT with lenalidomide maintenance. Achieved VGPR, post-ASCT.

May 30, 2024 | nature.com | Andriy Derkach |Bruno Costa |David Chung |Heather Landau |Oscar B. Lahoud |Hani Hassoun | +8 more

AbstractB-cell-maturation-antigen (BCMA)-directed therapies are highly active for multiple myeloma, but infections are emerging as a major challenge. In this retrospective, single-center analysis we evaluated infectious complications after BCMA-targeted chimeric-antigen-receptor T-cell therapy (CAR-T), bispecific-antibodies (BsAb) and antibody-drug-conjugates (ADC). The primary endpoint was severe (grade ≥3) infection incidence. Amongst 256 patients, 92 received CAR-T, 55 BsAb and 109 ADC.

Jul 25, 2023 | nature.com | Carlyn Tan |Andriy Derkach |Malin Hultcrantz |Sham Mailankody |Urvi A. Shah |Kylee H. Maclachlan | +7 more

AbstractLenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U.S. This single-center, retrospective study evaluated outcomes and safety of VRd and KRd. Primary endpoint was progression-free survival (PFS). Of 389 patients with newly diagnosed multiple myeloma, 198 received VRd and 191 received KRd. Median PFS was not reached (NR) in both groups; 5-year PFS was 56% (95%CI, 48–64%) for VRd and 67% (60–75%) for KRd (P = 0.027).

Mar 17, 2023 | nature.com | Sham Mailankody |Saurabh Chhabra |Surbhi Sidana

Authors and AffiliationsMyeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USASham MailankodyDepartment of Medicine, Weill Cornell Medical College, New York, NY, USASham MailankodyColorado Blood Cancer Institute, Denver, CO, USAJeffrey V.